A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
Latest Information Update: 31 Mar 2026
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Kailera Therapeutics
Most Recent Events
- 31 Mar 2026 New trial record